Cargando…
Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571238/ https://www.ncbi.nlm.nih.gov/pubmed/34491408 http://dx.doi.org/10.1007/s00262-021-03040-0 |
| _version_ | 1784594972745400320 |
|---|---|
| author | Reusing, Sarah B. Vallera, Dan A. Manser, Angela R. Watrin, Titus Bhatia, Sanil Felices, Martin Miller, Jeffrey S. Uhrberg, Markus Babor, Florian |
| author_facet | Reusing, Sarah B. Vallera, Dan A. Manser, Angela R. Watrin, Titus Bhatia, Sanil Felices, Martin Miller, Jeffrey S. Uhrberg, Markus Babor, Florian |
| author_sort | Reusing, Sarah B. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8571238 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85712382021-11-08 Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL Reusing, Sarah B. Vallera, Dan A. Manser, Angela R. Watrin, Titus Bhatia, Sanil Felices, Martin Miller, Jeffrey S. Uhrberg, Markus Babor, Florian Cancer Immunol Immunother Correction Springer Berlin Heidelberg 2021-09-07 2021 /pmc/articles/PMC8571238/ /pubmed/34491408 http://dx.doi.org/10.1007/s00262-021-03040-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Reusing, Sarah B. Vallera, Dan A. Manser, Angela R. Watrin, Titus Bhatia, Sanil Felices, Martin Miller, Jeffrey S. Uhrberg, Markus Babor, Florian Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL |
| title | Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL |
| title_full | Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL |
| title_fullStr | Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL |
| title_full_unstemmed | Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL |
| title_short | Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL |
| title_sort | correction to: cd16xcd33 bispecific killer cell engager (bike) as potential immunotherapeutic in pediatric patients with aml and biphenotypic all |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571238/ https://www.ncbi.nlm.nih.gov/pubmed/34491408 http://dx.doi.org/10.1007/s00262-021-03040-0 |
| work_keys_str_mv | AT reusingsarahb correctiontocd16xcd33bispecifickillercellengagerbikeaspotentialimmunotherapeuticinpediatricpatientswithamlandbiphenotypicall AT valleradana correctiontocd16xcd33bispecifickillercellengagerbikeaspotentialimmunotherapeuticinpediatricpatientswithamlandbiphenotypicall AT manserangelar correctiontocd16xcd33bispecifickillercellengagerbikeaspotentialimmunotherapeuticinpediatricpatientswithamlandbiphenotypicall AT watrintitus correctiontocd16xcd33bispecifickillercellengagerbikeaspotentialimmunotherapeuticinpediatricpatientswithamlandbiphenotypicall AT bhatiasanil correctiontocd16xcd33bispecifickillercellengagerbikeaspotentialimmunotherapeuticinpediatricpatientswithamlandbiphenotypicall AT felicesmartin correctiontocd16xcd33bispecifickillercellengagerbikeaspotentialimmunotherapeuticinpediatricpatientswithamlandbiphenotypicall AT millerjeffreys correctiontocd16xcd33bispecifickillercellengagerbikeaspotentialimmunotherapeuticinpediatricpatientswithamlandbiphenotypicall AT uhrbergmarkus correctiontocd16xcd33bispecifickillercellengagerbikeaspotentialimmunotherapeuticinpediatricpatientswithamlandbiphenotypicall AT baborflorian correctiontocd16xcd33bispecifickillercellengagerbikeaspotentialimmunotherapeuticinpediatricpatientswithamlandbiphenotypicall |